To improve the outcomes of kidney and pancreas transplant recipients through innovative and efficient clinical trials conducted by leading medical institutions around the world.
The inability to perform clinical trials that can be appropriately powered and enrolled in a reasonable time have been major barriers to developing new therapy. In addition, single-center practices and experience can vary widely leading to erroneous assumptions about expected outcomes and appropriate endpoints. To address these issues and to better perform an Adaptive Clinical Trial study, we established the Multicenter Transplant Alliance—Kidney (MTA-K) and -Pancreas (MTA-P) in 2015. Our group aims to improve long-term outcomes of kidney and pancreas transplant recipients.
The MTA is ideally suited to Adaptive Trial Design (ATD) clinical trials. Patient care protocols are standardized across the consortium. Collectively, the MTA-K performs approximately 1300 solitary kidney transplants each year which is 10% of all the kidney transplants in the US, while MTA-P performs approximately 20% of all pancreas transplants in the US. This ensures sufficient numbers of patients with specific phenotypes to do clinical trials. Patients in the MTA clinical trials are diverse and represent the entire spectrum of the US transplant population: 65 % are recipients of deceased donors and 40% are Hispanic or African American.
The MTA has a clearly-defined organizational structure with signed membership agreements approved by the legal departments of the various institutions. It is based on similar research consortia in oncology and HIV areas. The Coordinating Center is at Mayo Clinic, Rochester, MN and the Director is Dr. Mark D. Stegall, a transplant surgeon and researcher. Each site has a voting member on the Steering Committee. Members agree to share data via a common database (Medidata Rave) and research coordinators exist at each site with time devoted to the MTA activities
MTA Founded at Mayo Clinic - Rochester, MN
Design of Adaptive Clinical Trials & Launch of MTA Brand
First year of Clinical Trial Operations